Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Experimental therapies of Mycobacterium abscessus infections

Version 1 : Received: 11 August 2020 / Approved: 12 August 2020 / Online: 12 August 2020 (08:01:41 CEST)

A peer-reviewed article of this Preprint also exists.

Meir, M.; Barkan, D. Alternative and Experimental Therapies of Mycobacterium abscessus Infections. Int. J. Mol. Sci. 2020, 21, 6793. Meir, M.; Barkan, D. Alternative and Experimental Therapies of Mycobacterium abscessus Infections. Int. J. Mol. Sci. 2020, 21, 6793.

Journal reference: Int. J. Mol. Sci. 2020, 21, 6793
DOI: 10.3390/ijms21186793

Abstract

Mycobacterium abscessus is a non-tuberculous mycobacteria notoriously known for causing severe, chronic infections. Treatment of these infections is challenging due to either intrinsic or acquired resistance of M. abscessus to multiple antibiotics. Despite prolonged poly-antimicrobial therapy, treatment of M. abscessus infections often fails, leading to progressive morbidity and eventual mortality. Great research efforts are invested in finding new therapeutic options for M. abscessus. Clofazimine and rifabutin are known anti-mycobacterial antibiotics, repurposed for use against M. abscessus. Novel antimicrobials active against M. abscessus include delamanid, pretomanid and PIPD1 and the recently approved beta-lactamase inhibitors avibactam, relebactam and vaborbactam. Previously unused antimicrobial combinations e.g. vancomycin-clarithromycin and dual beta-lactam therapy have been shown to have synergistic effect against M. abscessus in experimental models, suggesting their possible use in multiple-drug regimens. Finally, engineered phage therapy has been reported to be clinically successful in a severe case of disseminated M. abscessus infection. While many of these experimental therapeutics have shown activity against M. abscessus in vitro, as well as intracellular and/or animal models, most have little if any evidence of effect in humans infections. Clinical studies of M. abscesssus treatments are needed in order to reliably determine the value of their incorporation in therapeutic regimens.

Subject Areas

Mycobacterium abscessus, drug treatment, experimental therapy, review,

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.